Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s ...

HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $7.50 ...

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...